NO20006086D0 - Fremgangsmåte for å redusere nivåer av homocystein og C- reaktive protein - Google Patents

Fremgangsmåte for å redusere nivåer av homocystein og C- reaktive protein

Info

Publication number
NO20006086D0
NO20006086D0 NO20006086A NO20006086A NO20006086D0 NO 20006086 D0 NO20006086 D0 NO 20006086D0 NO 20006086 A NO20006086 A NO 20006086A NO 20006086 A NO20006086 A NO 20006086A NO 20006086 D0 NO20006086 D0 NO 20006086D0
Authority
NO
Norway
Prior art keywords
homocysteine
procedure
reactive protein
reducing levels
levels
Prior art date
Application number
NO20006086A
Other languages
English (en)
Other versions
NO20006086L (no
Inventor
Pamela Wang Anderson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20006086D0 publication Critical patent/NO20006086D0/no
Publication of NO20006086L publication Critical patent/NO20006086L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
NO20006086A 1998-06-17 2000-11-30 Fremgangsmåte for å redusere nivåer av homocystein og C- reaktive protein NO20006086L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8960198P 1998-06-17 1998-06-17
PCT/US1999/012604 WO1999065306A1 (en) 1998-06-17 1999-06-04 Methods for reducing levels of homocysteine and c-reactive protein

Publications (2)

Publication Number Publication Date
NO20006086D0 true NO20006086D0 (no) 2000-11-30
NO20006086L NO20006086L (no) 2000-11-30

Family

ID=22218549

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006086A NO20006086L (no) 1998-06-17 2000-11-30 Fremgangsmåte for å redusere nivåer av homocystein og C- reaktive protein

Country Status (18)

Country Link
US (1) US6353003B1 (no)
EP (1) EP0966965A1 (no)
JP (1) JP2002518296A (no)
KR (1) KR20010052947A (no)
CN (1) CN1305342A (no)
AU (1) AU753035B2 (no)
BR (1) BR9911224A (no)
CA (1) CA2333384A1 (no)
EA (1) EA200100049A1 (no)
HR (1) HRP20000860A2 (no)
HU (1) HUP0102383A3 (no)
IL (1) IL138915A0 (no)
NO (1) NO20006086L (no)
PL (1) PL344841A1 (no)
SK (1) SK18802000A3 (no)
TR (1) TR200003713T2 (no)
WO (1) WO1999065306A1 (no)
ZA (1) ZA200005884B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004204675A1 (en) * 2003-01-06 2004-07-29 Wyeth The use of estrogen receptor alpha modulators for the treatment of multiphe sclerosis
US7196093B2 (en) * 2003-04-09 2007-03-27 General Atomics Reversible inhibitors of SAH hydrolase and uses thereof
US7517887B2 (en) * 2003-04-09 2009-04-14 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
US7868011B2 (en) * 2003-04-09 2011-01-11 General Atomics Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus
WO2004093882A1 (ja) * 2003-04-18 2004-11-04 Advanced Medicine Research Institute 眼に適用する疾患治療剤
US20070003600A1 (en) * 2003-06-11 2007-01-04 Carolyn Moore Methods for reducing c-reactive protein
TWI386204B (zh) * 2008-04-10 2013-02-21 Mitsubishi Tanabe Pharma Corp 高半胱胺酸合成酶抑制劑

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5075321A (en) 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
US5482949A (en) 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
US5445941A (en) 1993-06-21 1995-08-29 Eli Lilly And Company Method for screening anti-osteoporosis agents
US5441947A (en) 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
US5476862A (en) 1993-12-21 1995-12-19 Eli Lilly And Company Methods of increasing thrombomodulin expression
US5441965A (en) 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
ES2210089T3 (es) 1993-12-21 2004-07-01 Eli Lilly And Company Uso de raloxifeno y sus analogos para la fabricacion de un medicamento para la inhibicion de la oxidacion ldl y la ateroesclerosis.
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
JP4111352B2 (ja) 1996-05-21 2008-07-02 新日鐵住金ステンレス株式会社 ステンレス鋼の高清浄化精錬法
US6069175A (en) 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
US6025373A (en) 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen
US6103740A (en) 1997-08-21 2000-08-15 Eli Lilly And Company Methods for lowering platelet counts

Also Published As

Publication number Publication date
EA200100049A1 (ru) 2001-06-25
BR9911224A (pt) 2001-02-20
US6353003B1 (en) 2002-03-05
ZA200005884B (en) 2001-10-22
EP0966965A1 (en) 1999-12-29
PL344841A1 (en) 2001-11-19
CN1305342A (zh) 2001-07-25
WO1999065306A1 (en) 1999-12-23
JP2002518296A (ja) 2002-06-25
KR20010052947A (ko) 2001-06-25
HRP20000860A2 (en) 2001-10-31
NO20006086L (no) 2000-11-30
HUP0102383A2 (hu) 2002-01-28
AU4819299A (en) 2000-01-05
CA2333384A1 (en) 1999-12-23
TR200003713T2 (tr) 2001-04-20
SK18802000A3 (sk) 2001-09-11
AU753035B2 (en) 2002-10-03
HUP0102383A3 (en) 2003-01-28
IL138915A0 (en) 2001-11-25

Similar Documents

Publication Publication Date Title
DE69932575D1 (de) Sprachkodierer und sprachdekodierer
NO972125L (no) Hemorroideblandinger og fremgangsmåte for anvendelse
NO980890D0 (no) Kontroll av trafikk og transport
NO993217L (no) Broenntetningssammensetninger og fremgangsmåter
DE69836432D1 (de) Bildcoder und -decoder
DK1041879T3 (da) Desinfektionsmiddel og fremstillingsmetode
NO991150L (no) Pyrazolopyrimidiner og pyrazolotriaziner
NO991432D0 (no) Heterosykliske tioestere og ketoner
DK1454907T3 (da) Quninazolin og pyridopyrmidin-derivativer
DK0954588T3 (da) OB fusionsprotein-sammensætninger og fremgangsmåder
NO20022334L (no) Ny sammensetning og anvendelse
NO20006488D0 (no) Sammensetning og anvendelse
NO972983D0 (no) Sulfonamider og deres anvendelse
NO20001323D0 (no) Dipeptid-apoptose inhibitorer og deres anvendelse
NO20003427D0 (no) Lomasse og fremgangsmÕte for dens fremstilling
NO20012937D0 (no) Direkte spröytestöpt lukking og fremgangsmåte for denne
NO20012963L (no) Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
NO20004355L (no) Retarderende systemer og anvendelse derav ved oljebronnsementering
NO20012723D0 (no) Fremgangsmåte og system for prediktiv koding av datatabeller
NO981282D0 (no) Calcitriolderivater og deres anvendelser
NO20006086D0 (no) Fremgangsmåte for å redusere nivåer av homocystein og C- reaktive protein
NO990914D0 (no) Amorfe benzotiofener, fremgangsmÕter for fremstilling og fremgangsmÕter for anvendelse
PT1021200E (pt) Metodos e composicoes para o tratamento da artrite reumatoide
NO20013085D0 (no) Fosfororganiske forbindelser og deres anvendelse
NO984921D0 (no) Tienopyridinderivater og deres anvendelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application